VALO TX is developing novel immunotherapies for cancer and infectious disease that are projected to transform treatment and prevention for millions of patients. Our unique approach, based on the selective use of oncolytic and non-replicating vectors with disease-specific peptides, delivers a highly specific, immunogenic and rapidly adaptable platform for the treatment of cancer and for the prevention and treatment of infectious diseases.